CTC Detection and Enrichment Method Segment has the Largest Share of Technology in the Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market during 2021–2028

According to our latest study on “Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Technology, Application, and End User,” the market is projected to reach US$ 131.3 million by 2028 from US$ 75.3 million in 2021; it is expected to grow at a CAGR of 8.3% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing prevalence of cancer across the region along with rising demand for minimally invasive diagnostic procedures. However, dearth of skilled professionals performing diagnostic procedures is expected to restrict the market growth during the forecast period.

The outbreak of the COVID19 pandemic has reduced diagnostic services and screening programs, delaying the diagnosis of cancer. Cancer patients face many challenges during a pandemic, such as susceptibility to serious infections and interruption of cancer or standard medical care. Increased pressure from increased hospitalization rates for COVID19 patients has led to reprofiling of many hospitals and departments, including oncology clinics, to treat COVID19 patients. These factors are projected to hamper the growth of Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics market.

Based on technology, the circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. In 2021, the CTC detection and enrichment segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 10.2% in the forecast period.

Thermo Fisher Scientific, Stemcell Technologies, Inc, QIAGEN, Advanced Cell Diagnostics (Bio-Techne Corporation), and Fluxion Biosciences are among the leading companies in the Middle East & Africa circulating tumor cell (CTC) diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for circulating tumor cell (CTC) diagnostics market is segmented into technology, application, and end user. Based on technology, the Middle East & Africa circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. Based on application, the circulating tumor cell (CTC) diagnostics market is segmented into clinical/liquid biopsy, and research. Based on end user, the circulating tumor cell (CTC) diagnostics market is segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Geographically, the circulating tumor cell (CTC) diagnostics market is segmented into Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com